Wei et al. [37] conducted a meta-analysis reviewing clinical variables and identified several factors associated with a higher risk of ICI colitis, including combination therapy with ICI and chemotherapy and the use of anti-CTLA4 compared to anti-PD1 agents. This evidence concerns the gene CTLA4 and colitis.